Physician profile
Debora Vasquez
NPI 1154600955
$2,778.64
in general payments reported to CMS, 2019-2025
29 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $131 · 2022: $241 · 2023: $464 · 2024: $859 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $479.97 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $275.94 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $227.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $214.02 | 2024-2025 | |
| Abbvie INC. | $195.95 | 2019-2023 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $185.95 | 2019-2020 | |
| Exact Sciences Corporation | $180.46 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $142.90 | 2019-2020 | |
| Lilly USA, LLC | $139.24 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $97.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $80.24 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer Pharmaceuticals LLC | $73.75 | 2019 | |
| Vanda Pharmaceuticals INC. | $68.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.82 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $43.07 | 2019 | |
| Ethicon US, LLC | $36.03 | 2023 | Linx Reflux Management System |
| Merck Sharp & Dohme LLC | $29.81 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $29.04 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $24.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.34 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $18.93 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.63 | 2024 | Veozah |
| Abbott Laboratories | $18.52 | 2025 | Freestyle Libre 3 |
| Pbg Puerto Rico LLC | $17.23 | 2019 | |
| Lundbeck LLC | $16.91 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.77 | 2025 | Caplyta |
| Medicomp INC | $13.77 | 2023 | Telepatch Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.